English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.62 |
| Open | 3.65 |
| 1-Year Change | 47.18% |
| Day's Range | 3.62 - 3.78 |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. REL-1017, is a NMDA receptor (NMDAR) channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. The Company's clinical program for REL-1017 evaluates its potential as a rapid-acting, oral, once-daily antidepressant treatment.
BRIEF: For the fiscal year ended 31 December 2021, Relmada Therapeutics Inc revenues was not reported. Net loss increased from $59.5M to $125.8M. Higher net loss reflects Research and development - increase from $31.9M to $74.8M (expense), Stock-based Compensation in R&D increase from $4M to $15.8M (expense), Stock-based Compensation in SGA increase of 47% to $24.7M (expense).
.
